the risk assessment process should take account of such as the of medicines the history of falsified medicines in the end in third countries as well as the effects these falsified products have on
The risk-assessment process should take account of criteria such as the cost of medicines and the history of falsified medicines in the EU and in third countries, as well as the effects these falsified products have on public health, in terms of the specific nature of the products in question and of the severity of the conditions they are intended to treat.
The risk-assessment process should take account of such as the of medicines the history of falsified medicines in the and in third countries, as well as the effects these falsified products have on public health, in terms of specific nature of the products in question and of the of the conditions intended to treat.